The list price for most GLP-1 drugs, such as Ozempic and Wegovy, is more than $1,000 per month.

The biological mechanism of the peptide BPC-157 suggests a potential risk of accelerating the growth of existing tumors.

Robert F. Kennedy Jr. has directed the FDA to reconsider the regulatory status of several peptides that the Biden administration had previously placed on a banned list.

Some telehealth companies are legally selling compounded versions of GLP-1 drugs for approximately $250 to $300 per month.

In 2023, the Biden administration placed nearly 20 popular peptide compounds on the Category 2 list, restricting their use by compounding pharmacies.

The U.S. Food and Drug Administration's current position is that the sale of many popular gray market peptides is illegal.